XBI is a biotech-focused ETF offering equal-weight exposure to U.S. biotechnology companies. The SPDR S&P Biotech ETF tracks the performance of the S&P Biotechnology Select Industry Index. XBI ...
Tobi is a crypto writer at Investopedia. He aims to simplify the complex concepts of blockchain and cryptocurrencies for the masses. Julie Bang/ Investopedia More people need better medicines, and ...
With this in mind, let's check out a blastoff-ready biotech stock you'll kick yourself for not buying in 2026. Image source: Getty Images.
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 by 9 percentage ...
Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...
Apogee Therapeutics (NASDAQ: APGE) is one of the 17 biotechnology stocks with more than 50% upside. On January 25, Citi analyst Geoff Meacham maintained a Buy rating on Apogee Therapeutics ...
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results